Cisplatin and S-1 With or Without Nimotuzumab in Untreated Advanced Gastric Adenocarcinoma
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
In this open-label, single-center, small sample size, randomised, parallel-group, controlled
study, the investigators aim to assess efficacy and safety of addition of nimotuzumab to CS
chemotherapy in patients with previously untreated advanced gastric adenocarcinoma. Sixty-two
patients are required and randomly assigned (1:1) to each group.
The control regimen (CS chemotherapy) is recommended as the standard first-line regimen for
advanced adenocarcinoma of the stomach or gastroesophageal junction in japan.